Ray Dalio's LLY Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 73,292 shares of Eli Lilly and Company (LLY) worth $78.77 M, representing 0.29% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in LLY, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2023, adding 255,619 shares. Largest reduction occurred in Q2 2024, reducing 184,649 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Eli Lilly and Company (LLY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Eli Lilly and Company (LLY) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +62,851 | Add 601.96% | 73,292 | $1074.68 |
| Q3 2025 | +10,441 | New Buy | 10,441 | $763.00 |
| Q2 2025 | -2,746 | Sold Out | 0 | $0.00 |
| Q1 2025 | -81,610 | Reduce 96.74% | 2,746 | $825.91 |
| Q4 2024 | +11,085 | Add 15.13% | 84,356 | $772.00 |
| Q3 2024 | -22,466 | Reduce 23.47% | 73,271 | $885.94 |
| Q2 2024 | -184,649 | Reduce 65.86% | 95,737 | $905.38 |
| Q1 2024 | -37,200 | Reduce 11.71% | 280,386 | $777.96 |
| Q4 2023 | +255,619 | Add 412.51% | 317,586 | $582.92 |
| Q3 2023 | -51,918 | Reduce 45.59% | 61,967 | $537.13 |
| Q2 2023 | -145,381 | Reduce 56.07% | 113,885 | $468.98 |
| Q1 2023 | +28,528 | Add 12.36% | 259,266 | $343.42 |
| Q4 2022 | -58,115 | Reduce 20.12% | 230,738 | $365.84 |
| Q3 2022 | +84,028 | Add 41.02% | 288,853 | $323.35 |
| Q2 2022 | -42,521 | Reduce 17.19% | 204,825 | $324.23 |
| Q1 2022 | +124,227 | Add 100.90% | 247,346 | $286.37 |
| Q4 2021 | +76,737 | Add 165.45% | 123,119 | $276.22 |
| Q3 2021 | +20,316 | Add 77.94% | 46,382 | $231.06 |
| Q2 2021 | +26,066 | New Buy | 26,066 | $229.53 |
| Q2 2020 | -28,770 | Sold Out | 0 | $0.00 |
| Q1 2020 | +28,770 | New Buy | 28,770 | $138.72 |
| Q4 2019 | -8,135 | Sold Out | 0 | $0.00 |
| Q3 2019 | +8,135 | New Buy | 8,135 | $111.86 |
| Q4 2018 | -135,421 | Sold Out | 0 | $0.00 |
| Q3 2018 | -91,104 | Reduce 40.22% | 135,421 | $107.31 |
| Q2 2018 | +727 | Add 0.32% | 226,525 | $85.33 |
| Q1 2018 | +101,858 | Add 82.18% | 225,798 | $77.37 |
| Q4 2017 | +123,940 | New Buy | 123,940 | $84.46 |
| Q3 2017 | -51,151 | Sold Out | 0 | $0.00 |
| Q2 2017 | +51,151 | New Buy | 51,151 | $82.31 |
| Q1 2017 | -119,400 | Sold Out | 0 | $0.00 |
| Q4 2016 | +99,519 | Add 500.57% | 119,400 | $73.55 |
| Q3 2016 | -57,581 | Reduce 74.33% | 19,881 | $80.28 |
| Q2 2016 | +2,340 | Add 3.11% | 77,462 | $78.75 |
| Q1 2016 | +44,660 | Add 146.61% | 75,122 | $72.02 |
| Q4 2015 | +30,462 | New Buy | 30,462 | $84.27 |
| Q1 2015 | -4,639 | Sold Out | 0 | $0.00 |
| Q4 2014 | +4,639 | New Buy | 4,639 | $68.98 |
| Q2 2014 | -31,439 | Sold Out | 0 | $0.00 |
| Q1 2014 | -16,800 | Reduce 34.83% | 31,439 | $58.84 |
| Q4 2013 | +29,200 | Add 153.37% | 48,239 | $51.00 |
| Q3 2013 | +19,039 | New Buy | 19,039 | $50.32 |
Ray Dalio's Eli Lilly and Company Investment FAQs
Ray Dalio first purchased Eli Lilly and Company (LLY) in Q3 2013, acquiring 19,039 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Eli Lilly and Company (LLY) for 42 quarters since Q3 2013.
Ray Dalio's largest addition to Eli Lilly and Company (LLY) was in Q4 2023, adding 317,586 shares worth $185.13 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 73,292 shares of Eli Lilly and Company (LLY), valued at approximately $78.77 M.
As of the Q4 2025 filing, Eli Lilly and Company (LLY) represents approximately 0.29% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Eli Lilly and Company (LLY) was 317,586 shares, as reported at the end of Q4 2023.